Cancer affects us all. We can’t avoid it. But treatment has improved dramatically over the last 50 years.  New methods of surgery, radiotherapy and drugs have had a massive impact and the majority of patients are cured. Leading experts will consider the future and give their views on how to cure cancer.


In association with :



Prof. Karol Sikora


Prof. Karol Sikora

Dean, University of Buckingham Medical School

Karol’s forty years’ experience as an oncologist has taught him that the effectiveness of treatment is more important than the organisation behind its delivery. While he still remains a Consultant Oncologist at Hammersmith Hospital, where he was Clinical Director for over 15 years, he launched Cancer Partners UK, Britain’s largest independent network of innovative cancer treatment centres in 2009. As a Fellow of Corpus Christi College, Cambridge, and a Dean and Professor of Medicine at Buckingham University, he writes and lectures regularly on the use of biomarkers and surrogate endpoints by using molecular diagnostics to personalise therapy.

Prof. Sir John Burn


Prof. Sir John Burn

Chairman of QuantuMDx

Professor Sir John Burn obtained an MD with distinction, a first class honours degree in human genetics from Newcastle University, where he has been Professor of Clinical Genetics since 1991 and a consultant specialist since 1984. He led the regional NHS Genetics Service for 20 years and helped to create the Centre for Life which houses an education and science centre alongside the Institute of Genetic Medicine and Northgene Ltd, the identity testing company he launched in 1995. He chairs DNA device company QuantuMDx. He was knighted in 2010, chosen as one of the first 20 ‘local heroes’ to have a brass plaque on Newcastle Quayside in 2014. He received the Living North award in 2015 for services to the North East 2000 – 2015. He is also a non-Executive Director of NHS England.

Prof. Jayant S Vaidya


Prof. Jayant S Vaidya

Professor of Surgery and Oncology, University College London

Professional Jayant Vaidya has always enjoyed scientific discovery and as a surgeon and oncologist he has recognised that paradigm shifts in conceptual models of cancer are rare and it is the realisation of their need that leads to true progress. He is the professor of Surgery and Oncology at University College London and is consultant surgeon at its affiliated hospitals; he has published and lectured widely. His laboratory research led to the idea, device and the operative technique of restricting breast radiation to the tumour bed that would enable individualisation of radiotherapy; the efficacy of their novel approach was tested in one of the largest randomised clinical trials in the field.

Prof. Susan Short


Prof. Susan Short

Leeds Institute of Cancer and Pathology

Professor Susan Short is a clinical oncologist with a specialist research interest in treating adults with primary brain tumours. She trained at King’s College London and took up a post as Senior Lecturer at University College London in 2004, where she ran a translational research group as CRUK Clinician Scientist and Senior Fellow. She moved to Leeds in 2012 as professor of Clinical Oncology and Neuro-Oncology and currently leads the brain cancer research section at Leeds Institute of Cancer and Pathology.


Professor Short’s major research interests are in optimization of radiotherapy for patients with gliomas, particularly through improved understanding of mechanisms of radioresistance in stem cell populations.”

Prof. Paul Workman FRS FMedSci

Discovering and developing innovative new drugs

Prof. Paul Workman FRS FMedSci

Chief Executive and President, The Institute of Cancer Research London

Professor Paul Workman is Chief Executive and President of The Institute of Cancer Research in London. He is a passionate advocate of personalised molecular medicine, and is an enthusiastic practitioner of multidisciplinary cancer drug discovery and development approaches to ‘drugging the cancer genome’. Paul has been responsible for more than 20 molecularly targeted cancer drugs entering clinical trial, including protein kinase, PI3 kinase and HSP90 inhibitors. He founded Chroma Therapeutics and Piramed Pharma and has won numerous awards, including being elected as a Fellow of the Royal Society in 2016.

Prof. Kevin Harrington BSc(Hons) MBBS(Hons) MRCP FRCR FRCP DIC PhD


Prof. Kevin Harrington BSc(Hons) MBBS(Hons) MRCP FRCR FRCP DIC PhD

The Institute of Cancer Research/Royal Marsden Hospital

Professor Kevin Harrington specialises in developing new treatments with a specific focus on head and neck cancer and melanoma.


In 2016, he was appointed as a NIHR Senior Investigator. He is Joint Leader of the Division of Radiotherapy and Imaging at The Institute of Cancer Research/Royal Marsden Hospital and Biomedical Research Centre theme lead for radiotherapy research.


Prof. Harrington is a Fellow of the Royal College of Physicians and a Fellow of the Royal College of Radiologists. He has published more than 450 peer-reviewed papers, 45 book chapters and has edited 3 books.

Prof. Nandita M. deSouza


Prof. Nandita M. deSouza

Professor of Translational Imaging The Institute of Cancer Research (ICR)

Nandita M. deSouza, Professor of Translational Imaging and Co-Director of the MRI Unit, The Institute of Cancer Research (ICR), UK.


Main interests: Oncological imaging with emphasis on gynaecological, prostate and breast tumours, using functional imaging techniques to understand biology, improve staging and monitor treatment response. She has a particular interest in delivery of emerging therapies such as high-intensity focussed ultrasound under real-time image guidance. Nandita holds a Cancer Research UK Imaging Centre grant as Co-Principal Investigator.

Dr Ajay Aggarwal

Costs of cancer care

Dr Ajay Aggarwal

Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Trust

Dr Ajay Aggarwal is a Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Trust and Honorary Senior Lecturer at King’s College London in the Department of Cancer Epidemiology, Population and Global Health.


His main research interests centre upon the development of strategies for the delivery of affordable and equitable cancer care in developed and emerging economies. He recently completed a NIHR doctoral research fellowship at the London School of Hygiene and Tropical Medicine in the Department of Health Services Research and Policy where he investigated the impact of patient choice, hospital competition and service centralisation policies on NHS cancer services, specifically their effect on patient mobility, technology adoption and system reconfiguration.



Chairs: Prof. Paul Workman and Prof. Karol Sikora – Introduction


Prof. John Burn – Genetics


Prof. Jayant S Vaidya – Surgery


Prof. Susan Short – Radiotherapy


Prof. Paul Workman – Discovering and developing innovative new drugs


Prof. Kevin Harrington – Immunotherapy


Prof. Nandita de Souza – Imaging


Dr. Ajay Aggarwal – Costs of cancer care


Prof. Paul Workman and Prof. Karol Sikora – Conclusion


Royal Institution

21 Albemarle Street London W1S 4BS ‎ UK

Tube: Green Park, Bond Street, Oxford Circus, Piccadilly Circus
Bus: 9, 14, 19, 22 and 38